Summary of roundtable discussion meeting: Non-human primates to assess risk for EBV-related lymphomas in humans

T Kawabata, J Weaver, D Thomas, Martin Rowe, F Wang, C Kamperschroer, H Haggerty

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)

Abstract

Epstein-Barr virus (EBV)-associated lymphomas are a known risk for immunosuppressed individuals. Non-clinical methods to determine the potential of new immunomodulatory compounds to produce EBV-associated lymphomas (hazard identification) have not been developed. Since lymphocryptovirus (LCV) in non-human primates (NHP) has similar characteristics to EBV in humans, a Roundtable meeting was held in October 2010 to explore how the potential for EBV-related lymphomas in humans can be assessed by using surrogate biomarkers for lymphoma risk in NHP toxicity studies. Stakeholders from regulatory agencies, academia, and industry came together to determine the research gaps and potential benefits and considerations of such an approach given the current state-of-the-science. Key conclusions from the discussion included considerations raised about the potential usefulness of LCV-related biomarkers from NHP studies since there is significant controversy over the reliability of using EBV viral load or EBV-specific T-lymphocytes to predict for lymphoproliferative disorders in transplant patients. In addition, there are technical challenges that need to be further addressed in order to develop methods to measure LCV viral load and LCV-specific T-lymphocytes from cynomolgus monkeys.
Original languageEnglish
Pages (from-to)121-127
Number of pages7
JournalJournal of Immunotoxicology
Volume9
Issue number1
DOIs
Publication statusPublished - 1 Jan 2012

Keywords

  • Immunotoxicology
  • Epstein-Barr virus
  • non-human primates
  • immunotoxicity
  • lymphoma
  • monkey

Fingerprint

Dive into the research topics of 'Summary of roundtable discussion meeting: Non-human primates to assess risk for EBV-related lymphomas in humans'. Together they form a unique fingerprint.

Cite this